These issues have already emerged regarding their use in obesity and T2D
Additionally, it will: Delay stomach emptying, leading to a feeling of fullness and smaller meal size Slow intestinal motility Lowers blood sugars, in part by reducing the production of sugar in the liver Stimulates insulin secretion by the pancreas We start our patients off at a low dose and gradually increase the dose weekly
Although robust human evidence remains limited, it has become one of the most discussed recovery peptides in sports medicine and regenerative health
According to the MHRA/EMC SmPC, these include nausea (occurring in approximately 44% of patients in clinical trials), vomiting, diarrhoea, constipation, and abdominal discomfort
Your individual timeline depends on your genetic sensitivity to GLP-1, baseline pressure levels, and dose progression rate